New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
07:22 EDTRXIIRXi Pharmaceuticals announces results of Phase 1 RXI-109 study
RXi Pharmaceuticals announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects. This drug candidate is a highly selective CTGF targeting sd-rxRNA compound that is administered through intradermal injections to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. In this study, 15 volunteers divided over 5 cohorts received single intradermal injections in a dose escalating manner, and blood was drawn at various time points to evaluate the distribution of the drug beyond the injected tissue, into the systemic circulation. Previous primate toxicology work with RXI-109 had shown that the peak blood levels obtained after intradermal injections with 10 mg/kg were approximately 3.5% of the peak levels obtained after intravenous injections with the same dose. With the different doses in the primate study, the dermal and systemic side effects in the animals were minimal. The calculated relative systemic exposure in the 15 volunteers was between 1 and 7% which is very similar to the systemic exposure in primates. As reported earlier, the drug was very well tolerated in all volunteers tested.
News For RXII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
07:06 EDTRXIIRXi Pharmaceuticals granted Notice of Allowance from USPTO for use of technology
Subscribe for More Information
September 28, 2015
07:05 EDTRXIIRXi Pharmaceuticals granted patent in China for RXI-109
RXi Pharmaceuticals announced that it has been granted a patent from the State Intellectual Property Office of the People's Republic of China for the composition and methods of use for RXI-109 and other connective tissue growth factor targeting self-delivering RNAi compounds for the treatment of fibrotic disorders, including skin fibrosis. The patent is scheduled to expire in 2031. RXI-109 and other CTGF-targeting sd-rxRNA(R) compounds may be beneficial for the treatment of fibrotic diseases, including dermal scarring, a condition with a much higher prevalence in people with darker skin. Skin pigmentation is classified in VI categories known as the Fitzpatrick scale. In China, individuals tend to have skin types between III and V. The prevalence rates for hypertrophic scarring in individuals with higher-scoring Fitzpatrick phototypes can be up to 40-70% following surgery, making China a significant market for RXI-109 in the treatment of dermal scarring. According to Persistence Market Research, China is predicted to be one of the fastest growing markets for scar treatments in Asia.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use